On October 22, patients, physicians, and other interested parties will have the opportunity to provide input on the value and cost of mavacamten – the first drug specifically designed to treat hypertrophic cardiomyopathy.
Subscription RSS Feed: https://hcmbeat.com/feed/
Keep up with podcasts like this
If you find resources like this helpful, consider subscribing to our newsletter so you can have the latest news, analyses, podcasts, and videos mailed to you.
We'd really like to hear what you think about any of the podcasts we share here, our site, or anything we can do to be more useful for you. Thank you!